News Briefing channel feed

Lyn­parza se­cures third EU nod; Pro­tein degra­da­tion biotech grabs $16M launch round from Chi­nese VCs; Wave shares tum­ble on tri­al de­lay

7 years ago

WuXi AppTec re­cruits new CMO; Em­bat­tled Alk­er­mes makes case for ex­pand­ed use of schiz­o­phre­nia drug Aris­ta­da

7 years ago

TKI biotech lays out plans to raise about $125M in IPO; Hookipa sets terms for up­sized $100M IPO

7 years ago

Bay­er re­ports cy­ber at­tack point­ed to Chi­nese hack­ers; FDA pro­longs re­view of Dai­ichi Sanky­o's AML drug

7 years ago

Cit­ing patent in­fringe­ment, Lipocine sues Clarus; Sang­amo, DBV un­veil share of­fer­ings

7 years ago

Cigna/Ex­press Scripts of­fer di­a­bet­ics $25/month in­sulin; Pfiz­er's Viz­im­pro scores EU nod

7 years ago

Ru­bius cites some pre­clin­i­cal progress; Xen­cor scores deal with Astel­las; Ei­dos to re­state quar­ter­ly fil­ings

7 years ago

Mer­ck­'s Keytru­da wins first check­point in­hibitor lung can­cer ap­proval in Chi­na; Puma sells rights to Ner­l­ynx in Eu­rope, parts of Africa for $60M up­front

7 years ago

Rare dis­ease gene ther­a­py gains Prime sta­tus; FDA ap­proves first drug for in­flam­ma­to­ry arthri­tis nr-axS­pA

7 years ago

Three biotechs raise $100M+ in fund­ing for gene ther­a­pies, can­cer vac­cines and more

7 years ago

Louisiana sub­scribes to Gilead­'s Net­flix-style plan for hep C; Ono is in­vest­ing mil­lions in a new I/O re­search al­liance

7 years ago

Prome­dior makes a 'break­through' with PhI­II IPF drug; NASH fo­cused NGM Bio­phar­ma sets terms for IPO; blue­bird bio says Lenti­Glo­bin is still un­der EU re­view, de­spite con­flict­ing re­port

7 years ago

J&J, Bay­er agree to $775M pay­out to set­tle Xarel­to lit­i­ga­tion; Bio­gen launch­es $5B buy­back in the wake of a dis­as­ter; Hookipa pitch­es $86M IPO

7 years ago

No­var­tis' Al­con unit set for Swiss/NYSE de­but on April 9; Novo's keen­ly an­tic­i­pat­ed oral GLP-1 sub­mit­ted for speedy US re­view

7 years ago

Roivan­t's rare dis­ease shop cap­tures FDA des­ig­na­tions; Chi­na biotech lands $18M launch round

7 years ago

To tack­le soar­ing pre­scrip­tion drug costs, Cana­da cre­ates new agency to ne­go­ti­ate prices; DMC clears phI­II test­ing of Cy­to­ki­net­ic­s' Am­gen-part­nered heart drug

7 years ago

Af­fimed lands mile­stone from Roche; Puma touts new PHII da­ta on cer­vi­cal can­cer

7 years ago

Aim­mune wins 12-month re­view and ad­com for peanut al­ler­gy drug; Phase­Bio flies on ear­ly da­ta for Bril­in­ta re­ver­sal agent

7 years ago

Gen­fit read­ies its $120M IPO; Karyopharm shares boost­ed af­ter an FDA de­lay for se­linex­or

7 years ago

Biotech C4 raids NI­BR for new CMO; EU reg­u­la­tors green­light Hem­li­bra ex­pand­ed la­bel

7 years ago

Cam­bridge's TriNetX rais­es $40M for clin­i­cal an­a­lyt­ics plat­form; Nov­aBay chops its sales force, ap­points new chief

7 years ago

Neu­ro­crine breaks out proof-of-con­cept da­ta for CAH drug; Ake­bia, MT­PC work to­ward Japan­ese NDA af­ter ane­mia drug scores in twin PhI­I­Is

7 years ago

Take­da touts a land­mark head-to-head PhI­I­Ib win over Hu­mi­ra; Al­ler­gan's oral CGRP is now un­der FDA re­view

7 years ago

Dupix­ent scores speedy re­view for rhi­nos­i­nusi­tis with nasal polyps; Af­ter trans­plant, third pa­tient is HIV-free for 3 months

7 years ago
First page Previous page 51525354555657 Next page Last page
A service from the Financial Times